Standard Article

Clinical Trials on Cognitive Drugs

Clinical Trials

  1. Elisabetta Farina,
  2. Francesca Baglio

Published Online: 15 MAR 2010

DOI: 10.1002/9780470571224.pse230

Pharmaceutical Sciences Encyclopedia

Pharmaceutical Sciences Encyclopedia

How to Cite

Farina, E. and Baglio, F. 2010. Clinical Trials on Cognitive Drugs. Pharmaceutical Sciences Encyclopedia. 230:1–28.

Author Information

  1. Neurorehabilitation Unit, Don Carlo Gnocchi Foundation, Scientific Institute and University, IRCCS, Milan, Italy

Publication History

  1. Published Online: 15 MAR 2010


Cognitive disabilities, especially memory disturbances and cognitive deficits, posttraumatic brain injury (TBI), and poststroke are important targets for clinical pharmacological trials due to their important epidemiological and social impact. Brain changes leading to cognitive decline and dementia, and their relation to disability, are key topics requiring investigation at the population level. It is expected that pharmacological approaches will become increasingly integrated with behavioral, genetic, and neuroimaging methods to investigate disease processes and the normal and preclinical individual differences that underlie successful— or unsuccessful—aging.


  • dementia;
  • trauma;
  • stroke;
  • safety evaluation;
  • quality-of-life